Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06145113
Other study ID # 23-2158
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 10, 2024
Est. completion date August 10, 2024

Study information

Verified date November 2023
Source University of Colorado, Denver
Contact Brian M Strickland, MD
Phone 9139619491
Email brian.strickland@cuanschutz.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute Mountain Sickness (AMS) is a common condition affecting individuals traveling to elevations greater than 2500 meters (8200 feet). While more gradual ascent profiles, as well as the use of acetazolamide, have been shown to decrease the incidence of AMS, it remains a common condition that can affect anyone who travels to altitude. Many pharmacologic options for treatment of AMS exist, however these are not always effective or able to be taken by all patients. Continuous positive airway pressure (CPAP) has been shown in some small studies and reports to be a potential non-pharmacologic method of both preventing and treating AMS. No large trials to validate the efficacy of CPAP in altitude related illness have been done. This study aims to evaluate the degree to which CPAP can improve symptoms of AMS, as well as improve oxygen saturation among individuals traveling in a high altitude location.


Description:

AMS is commonly experienced among travelers in all high altitude locations, and can affect anyone who travels to one of these places. This illness can be prevented, and after its symptoms have been started, can be treated with medication, as well as by descending to a lower elevation. The medications for AMS symptoms, including acetazolamide, dexamethasone, and ibuprofen are not always effective, and even when they are, often take considerable time to show their effect. Additionally, not all patients can take these medications. When these medications are not effective, or there is a contraindication to their use, descent to a lower elevation is necessary, however this is not always possible due to weather, debilitating symptoms, or coinciding diagnoses of high altitude pulmonary edema (HAPE) or high altitude cerebral edema (HACE). These situations require a difficult and complicated evacuation, requiring multiple rescuers and heavy equipment, or increased risk of clinical deterioration. CPAP has been shown to be a potential non-pharmacologic method of both preventing and treating AMS. These limited studies quantified symptoms using the Lake Louise score {LLS}, a clinical tool used to assess the severity of AMS. They showed that LLS among subjects receiving CPAP, LLS lower when using it prophylactically or after AMS symptoms had started, however these were not compared against placebo. Additionally, over the last five years, CPAP devices have become quite portable and battery powered, making them much more suitable for travel to wilderness and high altitude locations. They are also available to consumers at low cost, are designed for travel and weigh less than 1 kg. Taking advantage of these devices' portability, a potential new treatment modality for AMS and other altitude related illnesses exists. Additionally, these devices can offer new solutions for mountain rescue and evacuation of patients suffering from altitude related illness, as these devices have been shown in a yet-to-be-published study to improve oxygen saturation and work of breathing while ambulating and self-carrying the device. Improvements in these assessments has been rapid (less than 2 minutes), potentially offering a more rapid treatment of AMS than existing pharmacologic agents as well. This study will be done in Pheriche, Nepal, as it is a location that has a uniquely elevated prevalence of altitude-related illness.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 75
Est. completion date August 10, 2024
Est. primary completion date June 10, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - present in Pheriche, Nepal; - Lake Louise score > 1 (with or without formal AMS diagnosis) Exclusion Criteria: - History of chronic respiratory conditions (uncontrolled asthma, COPD, ILD) - obstructive sleep apnea (if currently using nighttime CPAP) - congestive heart failure - coronary artery disease - history of myocardial infarction - neurologic disorder - cognitive disorder - altered mental status - pregnancy - current use of supplemental oxygen - excessive facial hair, - claustrophobia

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Continuous positive airway pressure (CPAP), ResMed AirMini
Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.

Locations

Country Name City State
Nepal Himalayan Rescue Association Pheriche

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver Himalayan Rescue Association

Country where clinical trial is conducted

Nepal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lake Louise score for symptoms of acute mountain sickness This is a validated set of criteria used for research purposes to quantify symptoms of acute mountain sickness.
A Lake Louise score greater than or equal to 3 is considered diagnostic of acute mountain sickness, and ranges from 0 to 15.
Higher Lake Louise scores are associated with more severe symptoms and level of disability.
The criteria are as follows:
Headache: 0-3 Gastrointestinal symptoms: 0-3 Fatigue and/or weakness: 0-3 Dizziness/light-headedness: 0-3 AMS Clinical Functional Score: 0-3
Prior to intervention, immediately following intervention, morning following intervention
Secondary Pulse oximetry Level of peripheral oxygen saturation as measured by pulse oximeter (0-100%) Prior to intervention, continuously while receiving intervention, immediately following intervention, morning following intervention
Secondary Heart rate Measured by palpation of peripheral pulses or pulse oximeter (beats per minute) Prior to intervention, continuously while receiving intervention, immediately following intervention, morning following intervention
Secondary Respiratory rate Measured by observation of chest rise and fall (breaths per minute) Prior to intervention, continuously while receiving intervention, immediately following intervention, morning following intervention
See also
  Status Clinical Trial Phase
Completed NCT04111263 - Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude N/A
Completed NCT01842906 - Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) N/A
Completed NCT01536288 - Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Phase 2
Completed NCT00326703 - Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort N/A
Completed NCT06310642 - Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness Phase 4
Completed NCT03561675 - Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Phase 4
Completed NCT00559832 - Prevention of Acute Mountain Sickness by Intermittent Hypoxia N/A
Completed NCT00603122 - Acclimatization Mechanisms During Ascent to 7500m N/A
Completed NCT01436383 - Oxidative Stress in Hypobaric Hypoxia N/A
Completed NCT00627965 - Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness Phase 4
Completed NCT00664001 - Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness Phase 3
Recruiting NCT05733338 - The Effects of Intermittent Hypoxia on Acute Hypoxic Injury N/A
Completed NCT01522326 - Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness N/A
Recruiting NCT06393998 - CO2 Supplement for Treatment of Acute Mountain Sickness N/A
Completed NCT03270787 - Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Phase 1/Phase 2
Completed NCT02811016 - Inhaled Budesonide and Acute Mountain Sickness Phase 1
Recruiting NCT00886912 - Training in Hypoxia to Prevent Acute Mountain Sickness N/A
Terminated NCT03956472 - Alternative Treatments in Acute Mountain Sickness N/A
Recruiting NCT03621410 - T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent Phase 2
Active, not recruiting NCT01565603 - Sleep and Cerebral Responses to High Altitude N/A